Wells Fargo has lowered its price target for HCA Healthcare to $369 from $428 following the company's revised 2026 financial outlook. HCA Healthcare reduced its earnings per share forecast to $28.70-$30.50 and narrowed sales guidance to $77-$79.5 billion due to a shift in payer mix and an increase in uninsured patients. Despite this, HCA reported strong Q2 revenue growth to $20.23 billion and increased patient admissions, indicating sustained demand for its services. The cautious outlook reflects challenges in the healthcare market but also highlights operational strength.
Kirby McInerney LLP is investigating HCA Healthcare for potential securities fraud following the company's sharp profit guidance cut due to increased uninsured patients affecting revenue by $400 million. The investigation aims to determine if HCA or ...
HCA Healthcare announced a significant cut to its full-year 2026 profit guidance due to an unfavorable change in its payer mix, which reduced revenue by about $400 million in Q2. Following this announcement, HCA's stock price fell nearly 7%. Pomerant...
